Publications by authors named "C Bonnefin"
Introduction: Immune checkpoint inhibitors (ICI) have become the first-line therapy in patients with advanced cutaneous squamous cell carcinoma (cSCC). Antibiotics (ATB) have been reported to reduce ICI response in cancers, but this has not been evaluated in cSCC.
Aim: To evaluate ATB exposure at the onset of ICI in cSCC patients and to analyze its impact on outcome.
Article Synopsis
- Combination BRAF/MEK inhibitors, used for treating metastatic melanoma, can improve patient survival but may lead to rare neurological adverse events (nAEs).
- A 42-year-old woman developed Parsonage-Turner syndrome, characterized by left shoulder pain and brachial plexopathy, shortly after starting encorafenib/binimetinib treatment following other immunotherapies.
- This case highlights the need for clinicians to be aware of potential neurological side effects from BRAF/MEK inhibitors, especially given their increasing use in melanoma treatment.